biostudies-literatureYau TMNHLBI NIH HHSCIHR1176-1186https://www.ebi.ac.uk/biostudies/studies/S-EPMC6439694biostudies-literatureUnknown321(12)<h4>Importance</h4>Left ventricular assist device (LVAD) therapy improves myocardial function, but few patients recover sufficiently for explant, which has focused attention on stem cells to augment cardiac recovery.<h4>Objective</h4>To assess efficacy and adverse effects of intramyocardial injections of mesenchymal precursor cells (MPCs) during LVAD implant.<h4>Design, setting, and participants</h4>A randomized phase 2 clinical trial involving patients with advanced heart failure, undergoing LVAD implant, at 19 North American centers (July 2015-August 2017). The 1-year follow-up ended August 2018.<h4>Interventions</h4>Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treatment in a 2:1 ratio (n = 106 vs n = 53).<h4>Main outcomes and measures</h4>JAMAIntramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial.PMC6439694U01 HL088942Maltais SGelijns ACJeffries NRose EAYau TMSoltesz EGMarks MEO'Sullivan KLParides MKMiller MAAcker MAHung JLala AMancini DMMilano CAMcGowan LKTaddei-Peters WCMoquete EGO'Gara PTCharbonneau EWoo YJBagiella EPagani FDMoskowitz AJKern JAPan SGreen CCardiothoracic Surgical Trials NetworkChang HLWeisel RDSelzman CHfalseIntramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial.<h4>Importance</h4>Left ventricular assist device (LVAD) therapy improves myocardial function, but few patients recover sufficiently for explant, which has focused attention on stem cells to augment cardiac recovery.<h4>Objective</h4>To assess efficacy and adverse effects of intramyocardial injections of mesenchymal precursor cells (MPCs) during LVAD implant.<h4>Design, setting, and participants</h4>A randomized phase 2 clinical trial involving patients with advanced heart failure, undergoing LVAD implant, at 19 North American centers (July 2015-August 2017). The 1-year follow-up ended August 2018.<h4>Interventions</h4>Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treatment in a 2:1 ratio (n = 106 vs n = 53).<h4>Main outcomes and measures</h4>2019-01-01T00:00:00Z2019 Mar2026-05-03T15:54:22.589Z2019-10-11T07:01:04ZS-EPMC64396943091283810.1001/jama.2019.2341